Breaking News
Get 45% Off 0
🌊 NVIDIA ripple effect: Track AI stocks' response to chip giant's earnings
Explore AI Stocks

Valeant (VRX) Touches 52-Week High: Is The Stock Officially Back?

By Zacks Investment ResearchStock MarketsDec 13, 2017 01:41AM ET
www.investing.com/analysis/valeant-vrx-touches-52week-high-is-the-stock-officially-back-200272992
Valeant (VRX) Touches 52-Week High: Is The Stock Officially Back?
By Zacks Investment Research   |  Dec 13, 2017 01:41AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
BHC
+2.12%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Shares of Valeant Pharmaceuticals (NYSE:VRX) surged more than 2% higher on Wednesday morning, touching a new 52-week high in the process. The embattled pharma stock continues to polarize investors, but its recent recovery is starting to gain momentum. As we approach the New Year, it is time to ask: is Valeant officially back?

Shares are still a long way from their highs of mid-2015, but the stock has climbed about 90% since the beginning of November. Valeant’s run comes as investors gear up for the company to begin sales of its new glaucoma treatment, Vyzulta, which should start this month.

Valeant Pharmaceuticals International, Inc. Price and Consensus

Valeant Pharmaceuticals International, Inc. Price and Consensus | Valeant Pharmaceuticals International, Inc. Quote

According to analysts surveyed by Bloomberg, Vyzulta is projected to generate about $174 million of revenue by 2021, while the company’s new ocular redness treatment, Luminesse, is expected to bring in about $38 million that year.

On top of Vyzulta and Luminesse, Valeant should benefit from sales of other new drugs, such as Siliq, a psoriasis medication, and IDP-118, a topical lotion that is currently being reviewed by the Food and Drug Administration.

Valeant has languished near $14 per share for most of the year. At those levels, new drug approvals attracted the attention of value investors, including Dimensional Fund Advisors LP, which more than tripled its stake in the pharma firm during the third quarter.

But Wall Street analysts remain lukewarm on both the stock and the company’s near-term prospects. The average analyst price target for VRX still sits at just $17, and earnings estimates for the upcoming fiscal year are not looking great.

Based on our latest consensus estimates, we expect Valeant to report full-year earnings of $3.59 per share in 2018. That figure would represent a 7% slump from this year’s projected full-year profits, which are expected to be down about 30%.

Valeant is finally starting to rebound, but investors should not expect volatility to disappear. However, the stock could be attractive to buy-and-hold investors looking to cash in on the company’s new drugs somewhere down the line.

Want more stock market analysis from this author? Make sure to follow @Ryan_McQueeney on Twitter!

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think.

See This Ticker Free >>



Valeant Pharmaceuticals International, Inc. (VRX): Free Stock Analysis Report

Original post

Zacks Investment Research

Valeant (VRX) Touches 52-Week High: Is The Stock Officially Back?
 

Related Articles

Valeant (VRX) Touches 52-Week High: Is The Stock Officially Back?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email